Nisa Investment Advisors LLC Buys 5,590 Shares of Axon Enterprise, Inc $AXON

Nisa Investment Advisors LLC raised its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 75.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,986 shares of the biotechnology company’s stock after buying an additional 5,590 shares during the period. Nisa Investment Advisors LLC’s holdings in Axon Enterprise were worth $9,319,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Westside Investment Management Inc. raised its stake in shares of Axon Enterprise by 4.8% during the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock valued at $225,000 after acquiring an additional 13 shares in the last quarter. CVA Family Office LLC grew its stake in Axon Enterprise by 26.9% in the second quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 14 shares in the last quarter. Newbridge Financial Services Group Inc. increased its holdings in Axon Enterprise by 2.8% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock worth $421,000 after purchasing an additional 14 shares during the period. Evergreen Capital Management LLC raised its position in Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares in the last quarter. Finally, STF Management LP raised its position in Axon Enterprise by 1.4% during the 2nd quarter. STF Management LP now owns 1,164 shares of the biotechnology company’s stock valued at $964,000 after purchasing an additional 16 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Price Performance

AXON opened at $631.69 on Friday. The firm has a market capitalization of $49.85 billion, a PE ratio of 199.90, a price-to-earnings-growth ratio of 19.89 and a beta of 1.41. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89. The business’s 50-day moving average is $572.86 and its two-hundred day moving average is $688.07. Axon Enterprise, Inc has a 1 year low of $469.24 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The firm had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. During the same period in the previous year, the company posted $1.45 earnings per share. The business’s quarterly revenue was up 30.6% compared to the same quarter last year. Research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AXON. Wall Street Zen downgraded Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Piper Sandler dropped their target price on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. UBS Group cut their target price on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Cowen restated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Finally, Barclays lowered their price target on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Fourteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $805.71.

Insider Buying and Selling

In other news, Director Jeri Williams sold 100 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $550.63, for a total transaction of $55,063.00. Following the completion of the sale, the director owned 1,316 shares in the company, valued at approximately $724,629.08. This represents a 7.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $552.60, for a total value of $11,052,000.00. Following the completion of the sale, the president directly owned 249,502 shares of the company’s stock, valued at $137,874,805.20. The trade was a 7.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 60,540 shares of company stock valued at $34,684,738 over the last quarter. Insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.